Table 1.

Demographic and baseline data between P and D+P groups

		P N = 172	D+P N = 129
Gender	Male	87 (50.6%)	61 (47.3%)
	Female	85 (49.4%)	68 (52.7%)
Age group (years)	< 1	21 (12.2%)	10 (7.8%)
	1 – 5	74 (43.0%)	53 (41.1%)
	6 – 10	53 (30.8%)	43 (33.3%)
	>10	24 (14.0%)	23 (17.8%)
Weight group (kg)	<10	19 (11.1%)	12 (9.3%)
	10 – 19	87 (50.6%)	61 (47.3%)
	20 – 40	42 (24.4%)	36 (27.9%)
	>40	24 (14.0%)	20 (15.5%)
ASA classification	1	16 (9.3%)	16 (12.4%)
	2	83 (48.3%)	47 (36.4%)
	3	73 (42.4%)	66 (51.2%)
Diagnosis by service	Endocrine	2 (1.2%)	0 (0%)
	ENT	7 (4.1%)	4 (3.1%)
	GastroIntestinal	10 (5.8%)	3 (2.3%)
	Hematology/Oncology	12 (7.0%)	12 (9.3%)
	NeuroSurgery	56 (32.6%)	34 (26.4%)
	Neurology	51 (29.7%)	38 (29.5%)
	Opthalmology	10 (5.8%)	12 (9.3%)
	Orthopedics	20 (11.6%)	17 (13.2%)
	Urology	4 (2.3%)	4 (3.1%)
	other	0 (0%)	5 (3.9%)
pre-existing condition affecting respiration	Yes	19 (11.1%)	14 (10.9%)
	No	153 (89.0%)	115 (89.1%)
MRI site	Head	96 (55.8%)	69 (53.5%)
	Spine	15 (8.7%)	16 (12.4%)
	Trunk	17 (9.9%)	12 (9.3%)
	Extremity	21 (12.1%)	11 (8.5%)
	Head & Spine	19 (11.0%)	20 (15.5%)
	Head & Trunk	1 (0.6%)	0 (0%)
	Trunk & Spine	2 (1.2%)	0 (0%)
	Extremity & Spine	1 (0.6%)	0 (0%)
	Trunk & Extremity	0 (0%)	1 (0.8%)
MRI Tesla	1.5T	104 (60.5%)	82 (63.6%)
	3T	68 (39.5%)	47 (36.4%)

group P, propofol only; group D+P, propofol infusion with dexmedetomidine bolus.

Statistical comparison is based on Chi-Square test.